 Home > Medical News > Latest Medical News > The first patient was administered to the first patient in the clinical trial of the pioneering pharmaceutical industry's ALK-1 monoclonal antibody combined with Corning Jereh KN046 in the treatment of advanced or refractory solid tumors

The first patient was administered to the first patient in the clinical trial of the pioneering pharmaceutical industry's ALK-1 monoclonal antibody combined with Corning Jereh KN046 in the treatment of advanced or refractory solid tumors

 Last Update: 2021-12-09
 Source: Internet
 Author: User

Tags

safety sunglasses

small single

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Suzhou, November 3, 2021/PRNewswire/ - On November 3, 2021, Kaifeng Pharmaceutical Co.

The study (NCT04984668) is a two-phase, multi-center, open-label phase Ib/II clinical trial designed to evaluate ALK-1 monoclonal antibody combined with KN046 in advanced or refractory solid tumors, including hepatocellular carcinoma (HCC) Safety, tolerability, pharmacokinetics (PK) and anti-tumor activity in patients with, gastric cancer and gastroesophageal junction adenocarcinoma (GC/GEJ), urothelial carcinoma (UC) and esophageal squamous cell carcinoma (ESCC)

Dr.

About ALK-1 monoclonal antibody

ALK-1 monoclonal antibody is a fully human IgG2 neutralizing antibody, which can inhibit ALK-1/TGF-β signal transduction and tumor angiogenesis.

At present, the clinical trial data of ALK-1 monoclonal antibody combination therapy in Taiwan, China announced on ASCO GI 2021 shows that the efficacy is encouraging and the safety is good, of which the objective response rate (ORR) reaches 40%

About KN046

KN046 is a PD-L1/CTLA-4 bispecific antibody independently developed by Corning Jereh.

KN046 has carried out nearly 20 clinical trials of different stages covering more than 10 types of tumors including non-small cell lung cancer, thymic cancer, pancreatic cancer, liver cancer, esophageal squamous cell carcinoma, triple negative breast cancer, etc.

About Kaixing Pharmaceutical

Founded in 2009, Kai Kuang Pharmaceutical focuses on the development and industrialization of potential "best-in-class" and "first-in-class" innovative drugs, and is committed to becoming a leader in the research, development and commercialization of innovative therapies

Corning Jereh Biopharmaceuticals focuses on the research and development, production and commercialization of innovative anti-tumor drugs

Source: Kaifeng Pharmaceutical

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.